type of breast cancer in women who have had treatment with other chemotherapy medications before surgery, but there was still cancer remaining in the tissue removed during surgery. Ado-trastuzumab emtansine is in a class of medications called antibody-drug conjugates. It works by killing cancer ...
Kadcyla (ado-trastuzumab emtansine) 产品说明书 Proprietary & Confidential © 2022 Magellan Health, Inc. Kadcyla® (ado-trastuzumab emtansine) (Intravenous) Document Number: IC-0092 Last Review Date: 07/20/2022 Date of Origin: 05/16/2013 Dates Reviewed: 07/2013, 11/2013, 12/2013, 03/...
The main purpose of this research study is to find out if de-escalation of chemotherapy before surgery followed by a selective escalation of adjuvant targeted therapies are efficacious and tolerable in early-stage HER2 positive breast cancer. ...
Kadcyla (ado-trastuzumab emtansine) is a new class ofchemotherapydrug called an antibody-drug conjugate used to treatbreast cancer. What Are Side Effects of Kadcyla? Common side effects of Kadcyla include: fatigue, tiredness, nausea, musculoskeletal pain, headache, constipation, lowplatelet count, l...
Preclinical studies demonstrate synergism with trastuzumab (T) and chemotherapy, as well as activity in models of HER2+ CNS dis... C Ferrario,E Hamilton,N Aucoin,... - 《Cancer Research》 被引量: 3发表: 2016年 加载更多研究点推荐 Ado-trastuzumab emtansine HER2-positive breast cancer antibody...
Ado-trastuzumab emtansine是一個革命性藥品,將單株抗體與傳統性化學藥品結合,用於治療固態性腫瘤.此藥具有相當高的專一性,藉著抗體引導細胞毒性藥品到達癌細胞,在不破壞其他正常細胞的情況下,直接攻擊癌細胞.它主要是由三個部份包括單株抗體trastuzumab,細胞毒性藥品emtansine以及連結物硫醚鍵(thioether linkage)所構成.臨...
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)Breast cancerChemotherapyFertilityPremenopausalAmenorrhea at 18months was less likely in recipients of adjuvant T-DM1 than TH. Future...
Ado-trastuzumab emtansine consists of the monoclonal antibody trastuzumab linked to a potent microtubule inhibitor (emtansine), allowing a targeted delivery of chemotherapy to cells that overexpress HER2. Ado-trastuzumab emtansine has been approved for use in patients with metastatic breast cancer who ...
von Minckwitz and colleagues (2018) noted that patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)-targeted therapy have a worse prognosis than those who have no residual cancer. Trastuzumab emtansine (T-DM1),...
Acceptable Cardiac Safety of Ado-Trastuzumab Emtansine After Anthracycline-Based Chemotherapy in Early-Stage HER2-Positive Breast CancerMatthew Stenger